ClinicalTrials.gg
CompletedNCT05394519REDEFINE 2Updated Jan 28, 2026

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

A Phase 3 interventional study of Cagrilintide and Semaglutide in Overweight, Obesity and Type 2 Diabetes Mellitus, sponsored by Novo Nordisk A/S. Completed at 179 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 9 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jan 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.

Enrollment
4th of 36
1,200 · median 154
Started
2023
with 4 others
Phase 3
15 of 36
4 open now
Registered
9th of 36
by date
Lead sponsor
36 of 36
Novo Nordisk A/S

Among the 36 studies testing cagrilintide in Obesity, this one is the 4th largest by enrollment, is one of 5 that started in 2023, is one of 15 in phase 3, and was the 9th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cagrilintide in Obesity, or all of them as a file.
02

Study summary

This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance.

The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

03

Conditions studied

  • Overweight
  • Obesity
  • Type 2 Diabetes Mellitus

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 1,200 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Age above or equal to 18 years at the time of signing
  • greather than or equal to 27.0 kg/m\^2
  • Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before screening
  • Treatment with either lifestyle intervention, or treatment with 1-3 marketed oral antidiabetic drugs (OAD)s (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose co-transporter 2 inhibitor (SGLT2i), thiazolidinediones, or sulphonylureas (SU)s as a single agent or in combination) according to local label
  • Treatment with oral antidiabetic drugs should be stable (same drug(s), dose and dosing frequency) for at least 90 days before screening
  • 7%-10% (53-86 mmol/mol) (both inclusive) as measured by the central laboratory at screening

Exclusion criteria

Exclusion Criteria:

  • or severe hypoglycaemia within 6 months before screening or history of hypoglycaemia unawareness
  • Renal impairment with estimated (eGFR) below 30 mL/min/1.73 m\^2, as measured by the central laboratory at screening
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,200 participants (actual)

Study arms

  • Experimental
    CagriSema

    Cagrilintide + semaglutide once weekly

    Drug: Cagrilintide · Drug: Semaglutide

  • Placebo comparator
    Placebo

    Placebo cagrilintide + semaglutide once weekly

    Drug: Placebo cagrilintide · Drug: Placebo semaglutide

Interventions

  • Cagrilintide administered subcutaneously (s.c., under the skin) once-weekly

  • Semaglutide administered subcutaneously (s.c., under the skin) once-weekly

  • DrugPlacebo cagrilintide

    Placebo cagrilintide administered subcutaneously (s.c., under the skin) once-weekly

  • DrugPlacebo semaglutide

    Placebo semaglutide administered subcutaneously (s.c., under the skin) once-weekly

07

What researchers measure

Primary outcomes

  1. Relative change in body weight

    Measured in percentage (%).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  2. Achievement of greater than or equal to (≥) 5% weight reduction

    Count of participant.

    Time frame: From baseline (week 0) to end of treatment (week 68)

Secondary outcomes

  1. Achievement of ≥ 20% weight reduction

    Count of participant.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  2. Relative change in body weight

    Measured in %.

    Time frame: From baseline (week 0) to week 20

  3. Change in waist circumference

    Measured in centimeter (cm).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  4. Change in Glycated Haemoglobin (HbA1c)

    Measured in %-points.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  5. Change in Systolic Blood Pressure (SBP)

    Measured in millimeter of mercury (mmHg).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  6. Change in Impact of Weight on Quality Of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function score

    Measured in score points.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  7. Change in Short Form-36 Version 2.0 Health Survey Acute (SF-36v2 Acute) Physical Functioning score

    Measured in score points.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  8. Change in body weight

    Measured in kilogram (kg).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  9. Change in body mass index (BMI)

    Measured in kilogram per meter square (kg/m\^2).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  10. Improvement in weight category (BMI, underweight below 18.5, normal weight 18.5 to below 25, overweight 25.0 to below 30, obesity class I 30 to below 35, obesity class II 35 to below 40, obesity class III above 40)

    Count of participant.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  11. Achievement of HbA1c less than or equal to (≤) 6.5%

    Count of participant.

    Time frame: At end of treatment (week 68)

  12. Change in Fasting Plasma Glucose (mmol/L)

    Measured in millimoles per liter (mmol/L).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  13. Change in Fasting Plasma Glucose (mg/dL)

    Measured in milligram per deciliter (mg/dL)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  14. Ratio to baseline in fasting serum insulin

    Measured in ratio.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  15. Change in Diastolic Blood Pressure (DBP)

    Measured in mmHg.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  16. Ratio to baseline in C-reactive protein (CRP)

    Measured in ratio.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  17. Ratio to baseline in lipids: Total cholesterol, High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Very low-density lipoprotein (VLDL) cholesterol, Triglycerides and Free fatty acids

    Measured in ratio.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  18. Change in IWQOL-Lite-CT: Total score, Physical and Psycosocial score

    IWQOL-Lite-CT is a 20-item clinical outcomes assessment (COA) instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score. Score ranges for composite score (physical composite, psychosocial composite and physical function composite) and Total score is 0-100. Higher scores indicate better level of functioning.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  19. Change in Control of Eating Questionnaire (CoEQ): Craving Control score, Positive Mood score, Craving for Sweet score, Craving for Savoury food score, Hunger score and Satiety score

    CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). Higher score represents a greater level of Craving Control.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  20. Achievement of at least 14.6-point increase (yes/no) in IWQOL-Lite-CT Physical Function score

    Count of participant.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  21. Achievement of at least 3.7-point increase (yes/no) in SF-36v2 Acute Physical Functioning score

    Count of participant.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  22. Change in IWQOL-Lite-CT Physical Function score

    Time frame: From baseline (week 0) to end of treatment (week 68)

  23. Achievement of at least 14.6-point increase (yes/no) in IWQOL-Lite -CT Physical Function score for subgroup

    Count of participant.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  24. Continuous glucose monitoring: Change in mean glucose (mmol/L)

    Measured in mmol/L.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  25. Continuous glucose monitoring: Change in mean glucose (mg/L)

    Measured in mg/L.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  26. CGM: Change in time above range (TAR) >10.0 mmol/L (>180 mg/dL)

    Measured in %-points.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  27. CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)

    Measured in %-points.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  28. CGM: Change in time above high range (TAHR) >13.9 mmol/L (>250 mg/dL)

    Measured in %-points.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  29. CGM: Change in time in tight range (TITR) 3.9-7.8 mmol/L (71-140 mg/dL)

    Measured in %-points.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  30. CGM: Within-day glycaemic variability (% CV)

    Measured in %.

    Time frame: At end of treatment (week 68)

  31. Number of Treatment Emergent Adverse Events (TEAEs)

    Count of events.

    Time frame: From baseline (week 0) to end of study (week 75)

  32. Number of Treatment Emergent Serious adverse events (TESAEs)

    Count of events.

    Time frame: From baseline (week 0) to end of study (week 75)

  33. Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol/L (54 mg/dL), confirmed by BG meter)

    Count of episodes.

    Time frame: From baseline (week 0) to end of study (week 75)

  34. Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold

    Count of episodes.

    Time frame: From baseline (week 0) to end of study (week 75)

08

Study locations

179 sites
  • John Muir Physicians Network
    Concord, California 94520, United States
  • Headlands Research California, LLC
    Escondido, California 92025, United States
  • Providence Medical Foundation
    Fullerton, California 92835, United States
  • St. Jos Heritage Hlthcr_Fllrtn
    Fullerton, California 92835, United States
  • Diabetes/Lipid Mgmt & Res Ctr
    Huntington Beach, California 92648, United States
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • Velocity Clin Res Los Angeles
    Los Angeles, California 90017, United States
  • Velocity Clin Res Wstlke
    Los Angeles, California 90057, United States
  • Desert Oasis Hlthcr Med Group
    Palm Springs, California 92262, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • New West Physicians,Inc.
    Golden, Colorado 80401, United States
  • Clinical Res Of W Florida Inc
    Clearwater, Florida 33765, United States
  • Northeast Research Institute
    Fleming Island, Florida 32003, United States
  • Jacksonville Ctr For Clin Res
    Jacksonville, Florida 32216, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • AdventHealth Diab Inst
    Orlando, Florida 32804, United States
  • Florida Institute for Clinical Research, LLC
    Orlando, Florida 32825, United States
  • Oviedo Medical Research, LLC
    Oviedo, Florida 32765, United States
  • Endo Res Solutions Inc
    Roswell, Georgia 30076, United States
  • East West Med Res Inst
    Honolulu, Hawaii 96814, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • Iowa Diab & Endo Res Center
    West Des Moines, Iowa 50266, United States
  • Cotton-Oneill Diabetes and End
    Topeka, Kansas 66606-2806, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Pennington Biom Res Ctr
    Baton Rouge, Louisiana 70808, United States
  • Northern Pines Hlth Ctr, PC
    Buckley, Michigan 49620, United States
  • International Diabetes Center
    Minneapolis, Minnesota 55416, United States
  • StudyMetrix Research LLC
    City of Saint Peters, Missouri 63303, United States
  • Mercury Str Med Grp, PLLC
    Butte, Montana 59701, United States
  • AMC Community Endocrinology
    Albany, New York 12203, United States
  • Southgate Medical Group, LLP
    West Seneca, New York 14224, United States
  • Great Lakes Medical Research
    Westfield, New York 14787, United States
  • PharmQuest Life Sciences LLC
    Greensboro, North Carolina 27408, United States
  • Hillcrest Clinical Research
    Simpsonville, South Carolina 29681-1538, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Amarillo Med Spec LLP
    Amarillo, Texas 79106, United States
  • Texas Diab & Endo, P.A.
    Austin, Texas 78731, United States
  • Texas Diab & Endo, P.A.
    Austin, Texas 78749, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • North Texas Endocrine Center
    Dallas, Texas 75231, United States
  • UT Southwestern Med Cntr
    Dallas, Texas 75390-9302, United States
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
  • DCOL Ctr for Clin Res
    Longview, Texas 75605, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Chrysalis Clinical Research
    St. George, Utah 84790, United States
  • National Clin Res Inc.
    Richmond, Virginia 23294, United States
  • Selma Medical Associates
    Winchester, Virginia 22601-3834, United States
  • Amherst Family Practice P.C.
    Winchester, Virginia 22601, United States
  • Capital Clin Res Ctr,LLC
    Olympia, Washington 98502, United States
  • Universitätsklinik für Innere Medizin Graz
    Graz, 8036, Austria
  • Barmh. Brüder Linz, Konventspital
    Linz, 4021, Austria
  • Fließer-Görzer [Ordination]
    Saint Stefan, 8511, Austria
  • Klinik Landstraße
    Vienna, 1030, Austria
  • Universitätsklinikum AKH Wien
    Vienna, 1090, Austria
  • Imed 19- privat
    Vienna, 1190, Austria
  • LMC Clin Res Inc. Calgary
    Calgary, Alberta T2H 2G4, Canada
  • C-endo Diab Endo Clin Calgery
    Calgary, Alberta T2V 4J2, Canada
  • Dr. M.B. Jones Inc
    Victoria, British Columbia V8V 4A1, Canada
  • Commonwealth Medical Clinic
    Mount Pearl, Newfoundland and Labrador A1N 1W7, Canada
  • Dr. Harpreet Bajaj
    Brampton, Ontario L6S 0C6, Canada
  • Centricity Research Etobicoke Endocrinology
    Etobicoke, Ontario M9R 4E1, Canada
  • Wharton Med Clin Trials
    Hamilton, Ontario L8L 5G8, Canada
  • Milestone Research
    London, Ontario N5W 6A2, Canada
  • LMC Research Inc. Ottawa
    Nepean, Ontario K2J 0V2, Canada
  • Diabetes Heart Research Centre
    Toronto, Ontario M6G 1M2, Canada
  • Centre Medical Acadie
    Montreal, Quebec H4N 2W2, Canada
  • Centricity Res Pointe-Claire
    Pointe-Claire, Quebec H9R 4S3, Canada
  • LMC Clin Rsrch Inc. (Montreal)
    Saint-Laurent, Quebec H4T 1Z9, Canada
  • Diabetespraxis Mergentheim
    Bad Mergentheim, 97980, Germany
  • Zentrum fuer klinische Studien Suedbrandenburg GmbH
    Elsterwerda, 04910, Germany
  • InnoDiab Forschung GmbH
    Essen, 45136, Germany
  • Universitätsklinikum Freiburg - Innere Medizin II
    Freiburg im Breisgau, 79106, Germany
  • Wendisch - Dahl Hamburg - DZHW
    Hamburg, 22607, Germany
  • AmBeNet GmbH
    Leipzig, 04107, Germany
  • Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
    Münster, 48145, Germany
  • Zentrum für klinische Studien Alexander Segner
    Saint Ingbert-Oberwürzbach, 66386, Germany
  • MZM Praxis Drs. Erlinger
    Stuttgart, 70378, Germany
  • Zentrum für klinische Studien Allgäu Oberschwaben
    Wangen, 88239, Germany
  • Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ
    Szeged, Csongrád-Csanád 6725, Hungary
  • Debreceni Egyetem Belgyógyászati Klinika
    Debrecen, Hajdú-Bihar 4032, Hungary
  • Hetényi Géza Kórház
    Szolnok, Jász-Nagykun-Szolnok 5000, Hungary
  • Komáromi Selye János Kórház
    Komárom, Komárom-Esztergom 2900, Hungary
  • Clinexpert Egészségügyi Szolgáltató és Kereskedelmi Kft.
    Budapest, 1033, Hungary
  • Szőcs Depot Egészségügyi Szolgáltató Kft.
    Budapest, 1042, Hungary
  • Bajcsy-Zsilinszky Kórház
    Budapest, 1106, Hungary
  • Selye János Kórház és Rendelőintézet
    Komárom, 2900, Hungary
  • Hetényi Géza Kórház
    Szolnok, 5004, Hungary
  • HCG Hospitals
    Ahmedabad, Gujarat 380006, India
  • Ramaiah Memorial Hospital
    Bangalore, Karnataka 560054, India
  • Calicut Medical College
    Kozhikode, Kerala 673008, India
  • Indian Institute of Diabetes
    Thiruvnanthapuram, Kerala 695033, India
  • Excel Endocrine Centre
    Kolhāpur, Maharashtra 416008, India
  • BYL Nair Hospital and T N Medical College Department of endo
    Mumbai, Maharashtra 400008, India
  • Seth GS medical college and KEM Hospital
    Mumbai, Maharashtra 400012, India
  • Sunil's Diabetes Care n' Research Centre Pvt Ltd
    Nagpur, Maharashtra 440010, India
  • Noble Hospitals Pvt Ltd.
    Pune, Maharashtra 411013, India
  • All India Institute of Medical Sciences_Delhi
    Ansārinagar, New Delhi 110029, India
  • Post Graduate Institute of Medical Education & Research_Chandigarh
    Chandigarh, Punjab 160012, India
  • J K Lon Hospital, SMS Medical College & Attached Hospitals
    Jaipur, Rajasthan 302004, India
  • SMS Medical College & Hospital
    Jaipur, Rajasthan 302004, India

Showing the first 100 of 179 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, Lingvay I, Lyndgaard CB, Rosenstock J, Pedersen SD; REDEFINE 2 Study Group. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025 Aug 14;393(7):648-659. doi: 10.1056/NEJMoa2502082. Epub 2025 Jun 22. PubMed 40544432 ↗

Individual participant data

Plan to share: Yes — "According to the Novo Nordisk disclosure commitment on novonordisk-trials.com"

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Jan 2025, 23 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 23 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2022
First posted
May 27, 2022
StartActual
Feb 1, 2023
Primary completionActual
Jan 28, 2025
CompletionActual
Feb 3, 2025
Results delay requested
Jan 26, 2026
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05394519
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 27, 2022
Start date
Feb 1, 2023
Primary completion
Jan 28, 2025
Completion
Feb 3, 2025
Last update
Jan 28, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion